- Biogen Inc BIIB and Ginkgo Bioworks have entered into a gene therapy collaboration to develop a next-generation adeno-associated virus (AAV)-based vectors production platform.
- Under the terms of the agreement, Ginkgo will utilize its cell programming platform and capabilities to enhance the AAV production titers of Biogen's gene therapy manufacturing processes.
- Ginkgo will receive an upfront payment of $5 million and is eligible for milestone payments up to an additional $115 million.
- Earlier this month, Ginkgo Bioworks announced a SPAC deal with Soaring Eagle Acquisition Corp SRNG that values the company at a pre-money equity value of $15 billion.
- Price Action: BIIB shares closed at $286.6 on Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
